tbuckley/cabot-search huggingface dataset:
Characteristics of elderly metastatic prostate cancer (M1 PC) long-term survivors in the SEER Medicare database receiving androgen-deprivation therapy (ADT)
Authors: N. A. Obeidat, C. D. Mullins, E. Onukwugha, B. Seal, A. Hussain
Journal: Journal of Clinical Oncology (2009)

e17513 Background: ADT remains standard treatment for pts with M1 PC, with radiation (RT) and chemotherapy (CT) providing additional palliation. This population-based analysis evaluated if long-term survivors (LT) receiving ADT possessed different characteristics relative to short-term survivors (ST). Methods: Pts age &gt;/= 66y in SEER Medicare diagnosed with M1 PC between 1998 and 2002 and receiving ADT with or without subsequent CT were identified. Median overall survival (OS) for the sample was used as a cut-off to categorize ST and LT pts. Within these categories, demographic, and clinical characteristics were evaluated. Results: 2,665 ADT pts were first identified who had median OS of 26 months (95% CI 24.0 - 27.0). 1,349 pts died at &lt;/= 26 months (ST pts), while 1,245 pts survived or were lost to follow-up beyond 26 months (LT pts). Median time to first treatment with ADT was 1 mo in both ST and LT groups. Within this 66y+ population, LT pts were younger (p &lt; 0.0001), more likely to be married (p = 0.0277), and were comprised of lower % of non-Hispanic white pts and higher % of ‘other’ races, but comparable % of African American and White-Hispanics (p = 0.0005). Distributional differences in PSA were detected, but interpreting the results was difficult due to missing or unknown information. Both ST and LT pts received RT and prostatectomy at similar rates, but LT pts had less comorbidities (p = 0.0008), and were more likely to receive CT (p = 0.0026). Conclusions: Long-term survivors were found to have demographic and clinical characteristics that differed from short-term survivors. Evidence regarding how these characteristics simultaneously impact the type and timing of treatment as well as survival deserve more exploration. [Table: see text]
A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM)
Authors: Chang Ki Min, Kihyun Kim, Seok Jin Kim, Dok Hyun Yoon, Sung-Soo Park, Seunghoon Han
Journal: Blood (2019)
Interplay of Coronary Artery Calcium and Risk Factors for Predicting CVD/CHD Mortality
Authors: Gowtham R. Grandhi, Mohammadhassan Mirbolouk, Zeina A. Dardari, Mouaz H. Al-Mallah, John A. Rumberger, Leslee J. Shaw, Ron Blankstein, Michael D. Miedema, Daniel S. Berman, Matthew J. Budoff, Harlan M. Krumholz, Michael J. Blaha, Khurram Nasir
Journal: JACC. Cardiovascular imaging (2019)

This study sought to evaluate the association and burden of coronary artery calcium (CAC) with long-term, cause-specific mortality across the spectrum of baseline risk.Although CAC is a known predictor of short-term, all-cause mortality, data on long-term and cause-specific mortality are inadequate.The CAC Consortium cohort is a multicenter cohort of 66,636 participants without coronary heart disease (CHD) who underwent CAC testing. The following risk factors (RFs) were considered: 1) current cigarette smoking; 2) dyslipidemia; 3) diabetes mellitus; 4) hypertension; and 5) family history of CHD.During the 12.5-years median follow-up, 3,158 (4.7%) deaths occurred; 32% were cardiovascular disease (CVD) deaths. Participants with CAC scores ≥400 had a significantly increased risk for CHD and CVD mortality (hazard ratio [HR]: 5.44; 95% confidence interval [CI]: 3.88 to 7.62; and HR: 4.15; 95% CI: 3.29 to 5.22, respectively) compared with CAC of 0. Participants with ≥3 RFs had a smaller increased risk for CHD and CVD mortality (HR: 2.09; 95% CI: 1.52 to 2.85; and HR: 1.84; 95% CI: 1.46 to 2.31, respectively) compared with those without RFs. Across RF strata, CAC added prognostic information. For example, participants without RFs but with CAC ≥400 had significantly higher all-cause, non-CVD, CVD, and CHD mortality rates compared with participants with ≥3 RFs and CAC of 0.Across the spectrum of RF burden, a higher CAC score was strongly associated with long-term, all-cause mortality and a greater proportion of deaths due to CVD and CHD. Absence of CAC identified people with a low risk over 12 years of follow-up, with most deaths being non-CVD in nature, regardless of RF burden.
CBMT-01. ALANINE FUELS ENERGY METABOLISM OF GLIOBLASTOMA CELLS
Authors: Omkar Ijare, David Baskin, Kumar Pichumani
Journal: Neuro-Oncology (2019)

Abstract Despite available aggressive treatment options, glioblastoma multiforme (GBM) has a median survival of 16 months indicating an urgent unmet need to develop new therapeutic strategies. Earlier, we have demonstrated that both glucose and acetate are the two major nutrients leading to synthesis of approximately ~60% acetyl-CoA in the brain tumors. Therefore, there must be other nutrients that may contribute to bioenergetic needs of highly proliferative GBM cells. Alanine is one of the non-essential amino acids (NEAA) that is constantly produced in cancer cells through Warburg glycolysis and its role in cancer metabolism is not well understood. Recently, it has been shown that alanine produced by pancreatic stellar cells contributed to the energy metabolism in pancreatic cancer cells. However, it is not known whether GBM can use alanine as an energy source. Here, we test whether GBM cells have the ability to metabolize alanine as a fuel to meet its increased energy requirements. Patient-derived GBM cells were cultured with 2.0 mM [3-13C]alanine for the final 24 hours, harvested in 50% methanol, snap-frozen in liquid N2, freeze-thaw cycle 3 times and lysates were stored at -80 °C. Derivatized material from the frozen lysates were used for GC-MS analysis to determine carbon mass isotopomer distribution (MID) of various glycolytic and TCA cycle intermediates. Our results indicated that [3-13C]alanine entered the GBM cells and produced [3-13C]lactate via pyruvate. Also, alanine-derived [3-13C]pyruvate led to the generation of [2-13C]acetyl-CoA, which entered TCA cycle and produced M+1 13C isotopomers of citrate, glutamate, malate and aspartate. MID showed the following 13C enrichment (M+1) values: citrate, 6.9 % ± 0.3%; glutamate, 4.4% ± 0.3%; malate, 2.1% ± 0.6%; 2.1% ± 0.5%. This preliminary data shows that GBM cells are capable of utilizing alanine to generate energy and produce precursors for biomolecular synthesis.
Disease Modeling of Severe Congenital Neutropenia Using CRISPR/Cas9 Gene Correction or Knockout of ELANE in Patients Derived Induced Pluripotent Stem Cells
Authors: Masoud Nasri, Benjamin Dannenmann, Perihan Mir, Malte U Ritter, Diana Amend, Yun Xu, Maksim Klimiankou, Cornelia Zeidler, Karl Welte, Julia Skokowa
Journal: Blood (2019)
DDIS-21. IN VITRO MICRODIALYSIS RECOVERY OF TRAMETINIB
Authors: Carlos Romo, Nicole Anders, Morgan Scardina, Debraj Mukherjee, Stuart Grossman, Jaishri O Blakeley, Michelle Rudek-Renaut
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Dysregulation of the mitogen-activated protein kinase and phosphoinositide 3-kinase (PI3K) pathways is common in several primary brain tumors and metastatic cancers affecting the central nervous system. Trametinib, and oral MEK1/2 inhibitor, has been effective in preclinical studies against a variety of cell lines and improves survival in select patients with gliomas. Unfortunately, limited and often short-lived benefits are frequently seen in patients. A potential explanation for this is insufficient blood brain barrier penetration at therapeutic concentrations. The primary objective of this study is to measure the in vitro relative recovery of trametinib using microdialysis to establish the feasibility of characterizing its intratumoral pharmacokinetics in vivo using this technique. METHODS In vitro recovery experiments were performed utilizing commercially available microdialysis instruments. Two perfusion rates (0.5–1µL/min), the use of iso- and hypertonic perfusates (artificial CSF and 10% bovine serum albumin in PBS), and the addition of dimethyl sulfoxide (DMSO) were evaluated using the extraction efficiency method. Liquid chromatography-tandem mass spectrometry was used to measure the concentrations of trametinib in stock solutions, dialysate samples, and controls over time. RESULTS Dialysate was initially collected from a solution spiked with 15ng/mL at a rate of 1µL/min for 60 minutes, the recovery was 0.3ng/mL (0.2%) in two samples and below the limit of quantification (&lt; 0.2ng/mL) in three. Dialysate samples were then collected from a stock solution with 150ng/mL of trametinib, recovery ranged from 0.3–15.3ng/mL (0.2–10.2%) in nine detectable samples out of sixteen. Recovery was greater with the addition of DMSO to the perfusate and with the use of a hypertonic perfusate. CONCLUSIONS The poor relative recovery of trametinib using microdialysis suggests that this technique would be unreliable in in vivo studies. Trametinib has poor aqueous solubility, limiting the ability of characterizing its pharmacokinetic profile through microdialysis.
Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Authors: Jinhong Fan, Hongbin Wang, Suzana Couto, Tsun-Wen Sheena Yao, Geoffrey L. Uy, Amer M. Zeidan, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Jamie Koprivnikar, Paresh Vyas, Yngvar Fløisand, María Belén Vidriales, Bjørn Tore Gjertsen, Tonia J. Buchholz, Michael Pourdehnad, Daniel W. Pierce
Journal: Blood (2019)
Distribution of somatic mutations in PIK3CA gene in breast colorectal and colorectal Czech cancer patients - selected colorectal cancer patients with angiogenesis inhibitors treatment
Authors: J. Simova, I. Urbanovská, R. Měch, J. Žmolíková, B. Kubová, K. Vaňáková, L. Trombík, N. Dvořáčková, J. Dvořáčková, J. Drábek, M. Uvírová
Journal: Annals of Oncology (2019)
Efficacy and Safety of DAC Combined with CAG Regimen (decitabine in combined with aclacinomycin, cytarabine and G-CSF) As a Second Induction Regimen Compared with Non-DAC Regimen for Acute Myeloid Leukemia Who Failed the First Course of Standard Induction IA Chemotherapy
Authors: Yili Chen, Min Dai, Qifa Liu
Journal: Blood (2019)
SURG-01. OPTIMALTTF-1: FINAL RESULTS OF A PHASE 1 STUDY: FIRST GLIOBLASTOMA RECURRENCE EXAMINING TARGETED SKULL REMODELING SURGERY TO ENHANCE TUMOR TREATING FIELDS STRENGTH
Authors: Anders Korshøj, Nikola Mikic, Slavka Lukacova, Jens Christian Sørensen, Frederik Hansen, Axel Thielscher, Søren Cortnum, Trine Guldberg, Yasmin Ramshad-Lassen, Christian Rahbek, Kåre Severinsen, Gorm von Oettingen
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND OptimalTTF-1(open-label phase-1) combines Tumor Treating Fields(TTFields) treatment with targeted skull-remodeling surgery(SR-surgery) aiming to enhance the electric field strength in the tumor(NCT02893137). SR-surgery aims to reduce the electrical impedance of the skull. Pre-clinical modeling indicates that SR-surgery increases the electric field strength. The final analysis examined toxicity and efficacy of TTFields combined with SR-surgery and best-choice-chemotherapy in first glioblastoma recurrence(rGBM). METHODS 18 patients were screened and 15 (4F/11M) enrolled between Dec2016 and Mar2019. The primary endpoint was frequency of serious adverse events (CTCAEv4.0) and secondary endpoints were overall survival (OS) and progression-free survival (PFS). Eligible patients were ≥18-years, had focal supratentorial rGBM, KPS≥70, and a minimum calculated increase in TTFields strength of ≥25% after SR-surgery. At the time-of-analysis patients were censored for time-to-event endpoints. RESULTS Baseline data(median (range)) demonstrated a patient age of 57(39;67), skull defect area=10.6 cm2(7;37), increase in the TTFields strength by 43%(25;59). All tumors were IDH-wt and 4 had MGMT-promoter methylation. In total, 4 patients were excluded from the study prior to TTFields initiation (consent withdrawal, radionecrosis/non-recurrence, postoperative infection and neurodeficit), 11 patients (2F/9M) underwent treatment. Treatment compliance was 90%(48;98), mean treatment duration and follow-up was 6.8 months(2.3;20.4) and 10 months respectively. Grade 1–2 AEs included, headache 60% CI95%=[32;84], fatigue 53%, CI95%=[27;79], skin rash 47%, CI95%=[21;73], and nausea 40%, CI95%=[16;68]. No grade 3 SAEs were related to the intervention (6 seizures, 1 headache, 1 fatigue, 1 TIA, 1 post-op infection, 1 diarrhea and 1 DVT). Efficacy outcomes were PFS6=64%, CI95%=[35;85], PFS=8.8 months, CI95%=[6.2;13.2], OS=15.0 months, CI95%=[9.6;16.2], and OS12=64%, CI95%=[35;85]. CONCLUSION Targeted SR-surgery combined with TTFields is safe and does not induce additional toxicity. Furthermore, it potentially increases overall survival in rGBM. A phase 2 clinical trial is currently being planned.
Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial
Authors: Christiane Querfeld, Basem M. William, Jonathan E. Brammer, Lubomir Sokol, Yutaka Tagaya, Paul Frohna, Nazli Azimi, Jasmine M. Zain
Journal: Blood (2019)
D-Dimer, P-Selectin, and Microparticles: Novel Markers To Predict Deep Venous Thrombosis.
Authors: John E. Rectenwald, Daniel D. Myers, Angela E. Hawley, Marisa J. Linn, Chathen R. Gangireddy, Peter K. Henke, Kenneth E. Guire, Alvin H. Schmaier, Thomas W. Wakefield
Journal: Blood (2004)
Novel Therapeutics That Can Target and Eradicate Leukemic Stem Cells in Acute Myeloid Leukemia: Investigating FDA-Approved Anti-Inflammatory Compounds
Authors: Isabella Iasenza, Meaghan Boileau, Andrea Neumann, Héloïse Frison, Mark D. Minden, Isabelle Laverdiere, Kolja Eppert
Journal: Blood (2019)
Sleep and HbA1c in Patients With Type 2 Diabetes: Which Sleep Characteristics Matter Most?
Authors: Annelies Brouwer, Daniel H. van Raalte, Femke Rutters, Petra J.M. Elders, Frank J. Snoek, Aartjan T.F. Beekman, Marijke A. Bremmer
Journal: Diabetes Care (2019)

Poor sleep has been identified as a risk factor for poor glycemic control in individuals with type 2 diabetes (T2D). As optimal sleep can be characterized in several ways, we evaluated which sleep characteristics are most strongly associated with glycated hemoglobin A1c (HbA1c).A total of 172 patients with T2D completed 7-day wrist-actigraphy and sleep questionnaires. Linear regression was used to evaluate associations between sleep measures (total sleep duration, variability in sleep duration, midsleep time, variability in midsleep time, sleep efficiency, subjective sleep quality, and subjective insomnia symptoms) and HbA1c, individually and in concert.Variability in sleep duration was individually most strongly associated with HbA1c (β = 0.239; P = 0.002; R2 = 4.9%), followed by total sleep duration (U-shaped: β = 1.161/β2 = 1.044; P = 0.017/0.032; R2 = 4.3%), subjective sleep quality (β = 0.191; P = 0.012; R2 = 3.6%), variability in midsleep time (β = 0.184; P = 0.016; R2 = 3.4%), and sleep efficiency (β = -0.150; R2 = 2.3%). Midsleep time and subjective insomnia symptoms were not associated with HbA1c. In combination, variability in sleep duration, total sleep duration, and subjective sleep quality were significantly associated with HbA1c, together explaining 10.3% of the variance in HbA1c. Analyses adjusted for covariates provided similar results, although the strength of associations was generally decreased and showing total sleep duration and subjective sleep quality to be most strongly associated with HbA1c, together explaining 6.0% of the variance in HbA1c.Sleep in general may be a modifiable factor of importance for patients with T2D. The prevention of sleep curtailment may serve as a primary focus in the sleep-centered management of T2D.
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Authors: Zhonghan Zhang, Fan Luo, Yang Zhang, Yuxiang Ma, Shaodong Hong, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang, Hongyun Zhao
Journal: Cancer Communications (2019)

Gefitinib, as the first epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC), has been proved to significantly improve the progression-free survival (PFS) in the first-line setting but suffers from resistance 7–10 months after treatment initiation. Apatinib (YN968D1), a potent vascular endothelial growth factor receptor (VEGFR) 2-TKI, specifically binds to VEGFR2 and leads to anti-angiogenetic and anti-neoplastic effect. Concurrent inhibition of VEGFR and EGFR pathways represents a rational approach to improve treatment responses and delay the onset of treatment resistance in EGFR-mutant NSCLC. This ACTIVE study aims to assess the combination of apatinib and gefitinib as a new treatment approach for EGFR-mutant NSCLC as a first-line setting. This multicenter, randomized, double-blind, placebo-controlled phase III study (NCT02824458) has been designed to assess the efficacy and safety of apatinib or placebo combined with gefitinib as a first-line treatment for patients with EGFR-mutant advanced NSCLC. A total of 310 patients with EGFR-mutation (19del or 21L858R), pathological stage IIIB to IV non-squamous NSCLC were to be enrolled. The primary endpoint is investigator assessment of PFS, and the secondary endpoints include independent radiological central (IRC)-confirmed PFS, overall survival (OS), objective response rate (ORR), disease control rate (DCR), time to progressive disease (TTPD), duration of response (DoR), quality of life (QoL) and safety. The patients are randomized in a 1:1 ratio to receive gefitinib (250 mg, p.o. q.d.) plus apatinib (500 mg, p.o. q.d.) or gefitinib plus placebo, given until disease progression or intolerable adverse events. Exploratory biomarker analysis will be performed. This study is being conducted across China and comprises of 30 participating centers. Enrollment commenced in August 2017 and finished in December 2018, most of the patients are in the follow-up period. The present study will be the first to evaluate the efficacy and safety profile of the combination of apatinib plus gefitinib as a first-line therapy for patients with EGFR-positive advanced non-squamous NSCLC. Importantly, this trial will provide comprehensive evidence on the treatment of EGFR-TKIs combined with antiangiogenic therapy. Trial registration Clinicaltrials.gov NCT02824458. Registered 23 June 2016
Neuropsychological Impairments in Hematological Malignancies Patients Expected to Allo-BMT
Authors: Dmitry E Vybornykh, Sergey O Khrushchev, Svetlana Yu Fedorova, Alexander Tkhostov, Ilia V Pluzhnikov, Larisa A. Kuzmina, Elena N. Parovichnikova, Valery G Savchenko
Journal: Blood (2016)
STEM-26. ALTERED LIPID METABOLISM MARKS GLIOBLASTOMA STEM AND NON-STEM CELLS IN SEPARATE TUMOR NICHES
Authors: Lisa Wallace, Anthony Gromovsky, James Hale, Arnon Knudsen, Briana Prager, Daniel Silver, Andrew Sloan, Bjarne Kristensen, Justin Lathia, J Mark Brown, Jeremy Rich, Christopher Hubert
Journal: Neuro-Oncology (2019)

Abstract Clinical glioblastoma is marked by a strikingly heterogeneous mix of cell types, cellular metabolisms, and cellular microenvironments spread in different spatial locations throughout a tumor. We have created 3-dimensional organoid models that partially mimic the transition zone between nutrient-rich cellular tumor regions and nutrient-poor psuedopallisading and perinecrotic tumor zones. We found a dramatic disparity in lipid droplet presence between these regions with high lipid accumulation in the hypoxic organoid cores of a wide spectrum of patient derived specimens. This is accompanied by regionally restricted upregulation of HILPDA gene expression in the cores of our models, in clinical GBM specimens but not lower grade brain tumors, and localized specifically to pseudopallisading regions of patient tumors. We further show that lipid droplet accumulation overall marks perinecrotic and pseudopallisading regions in clinical GBM, indicating broadly altered lipid metabolism between these distinct cell populations. High lipid droplet accumulation is largely restricted to the non-stem cell populations of GBM organoids and sorted xenograft tumors whereas the stem cells are lipid-poor, suggesting lipid levels may not be simply a product of the microenvironment but also may be a reflection of cell state. We performed global lipidomic analysis on prospectively sorted stem and non-stem cells of multiple patient-derived models and found that GBM stem cells have comparatively decreased levels of neutral lipids, indicating a significant metabolic shift compared to non-stem cells from the same patient. Conversely, GBM stem cells have significantly increased levels of rare specific lipid species, and also display altered phospholipid synthesis and species specific alterations in phospholipid classes. Our findings suggest avenues for therapy by targeting the altered lipid metabolic pathways of these disparate tumor cell populations.
Abstract 414: Role of Red Blood Cell Derived Extracellular Vesicles in Cardiac Remodeling After Myocardial Infarction in a Transgenic Murine Model
Authors: Avash Das, Olivia Ziegler, Kirsty Danielson, Bridget Simonson, Shulin Lu, Vasilis Toxavidis, Tigges John, Ionita Ghiran, Saumya Das
Journal: Circulation Research (2017)

Introduction: Extracellular vesicles (EVs) function as novel mediators of intercellular communication. Here, we describe a novel, fluorescence switch-based, experimental model to study EV-mediated communication between RBCs and the heart that permits characterization of cross-talk between RBCs and cardiomyocytes at homeostasis and after myocardial infarction. Methods: Mice with RBC-specific expression of cre (Erythropoietin Receptor (EpoR) Cre) were crossed with reporter mTmG Rosa26 mice to yield EpoRCre/mTmG off-springs with membrane GFP expression in RBCs and RBC-derived EVs. Cultured dermal fibroblasts from mTmG mice and a mT/floxed/mGFP HEK 293 reporter cell line were used to assess transfer of functional cre in RBC-derived EVs. To determine targets of RBC-EVs, organs from i)EpoRCre/mTmG (n=3), ii) mTmG (n=3) or iii) mTmG mice transfused with RBC-EVs from EpoR-cre mice and targets of RBC-EVs (determined by mGFP expression due to cre-recombination) were assessed by confocal microscopy. Finally, ischemia-reperfusion-infarction (30 min. LAD ligation) was done in EpoRCre/mGmT mice (n=3) and their blood and organs harvested after a span of 4 weeks to analyze changes in quality and quantity of RBC-EV targets following MI. Results: 1. RBC-EVs (mGFP positive) in plasma accounted for about 9% of total fluorescent EVs as detected by nano-flow cytometry and microscopy. 2. RBC-EVs contained cre protein by EM, and in vitro dermal fibroblasts from mTmG mice or mT/floxed/mGFP HEK 293 reporter cells showed mGFP expression with EpoRCre RBC-EVs, suggesting EV-mediated transfer of functional cre. 3. Cre-mediated recombination was noted in diverse organs in EpoRCre/mTmG mice and mTmTG mice transfused with EpoRCre- EVs with the bone marrow, heart, lungs, kidney and spleen showing the largest degree of recombined cells. 4. Target profile of RBC-EVs demonstrates a distinct pattern of EV-mediated communication among the organs at baseline that may be altered in different disease models. Conclusion: We show proof-of-concept for a novel model to study origin and targets of EV-mediated intercellular communication with significant EV-mediated communication between RBCs and cardiomyocytes under homeostatic conditions.
Clinical Significance of Additional Cytogenetic Abnormalities (ACA) at Disease Progression in Patients with High-Risk Myelodysplastic Syndrome (MDS) Treated with Azacitidine
Authors: Chiaki Naito, Hiroaki Shimizu, Yuri Miyazawa, Takuma Ishizaki, Akihiko Yokohama, Takayuki Saito, Norifumi Tsukamoto, Hiroshi Handa
Journal: Blood (2019)